Olpasiran (sodium)

Olpasiran sodium is a small interfering RNA that reduces lipoprotein (a) synthesis in the liver.

Product Specifications

Product Name Alternative

AMG 890 (sodium) ; ARC-LPA (sodium)

UNSPSC

12352208

Target

Small Interfering RNA (siRNA)

Type

Oligonucleotides

Related Pathways

Epigenetics

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/olpasiran-sodium.html

Purity

98.82

Solubility

10 mM in H2O

Smiles

[Olpasiran(sodium)]

Molecular Formula

C490H610F11N164Na42O306P41S7

Molecular Weight

15438.7 (free acid)

References & Citations

[1]Sohn W, Winkle P, Neutel J, et al. Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study. Clin Ther. 2022;44 (9) :1237-1247. |[2]O'Donoghue ML, G López JA, Knusel B, et al. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN (a) reduction-DOSE finding study (OCEAN (a) -DOSE) . Am Heart J. 2022;251:61-69.